Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diabetes

  Free Subscription


Articles published in Circulation

Retrieve available abstracts of 62 articles:
HTML format
Text format



Single Articles


    May 2018
  1. VERMA S, Bhatt DL, Bain SC, Buse JB, et al
    Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
    Circulation. 2018;137:2179-2183.
    PubMed     Text format    


  2. PACKER M
    Response by Packer to Letter Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchange Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure".
    Circulation. 2018;137:1981-1982.
    PubMed     Text format    


  3. GAZMURI RJ, Karmazyn M
    Letter by Gazmuri and Karmazyn Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure".
    Circulation. 2018;137:1979-1980.
    PubMed     Text format    


    April 2018
  4. HU L, Qi Z, Zhang S, Luo X, et al
    Response by Hu et al to Letters Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1877-1878.
    PubMed     Text format    


  5. GONG L, Li J, Yang G
    Letter by Gong et al Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1875-1876.
    PubMed     Text format    


  6. JIN-SHAN H, Xue-Bin L
    Letter by Jin-shan and Xue-bin Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1874.
    PubMed     Text format    


    March 2018
  7. RADHOLM K, Figtree G, Perkovic V, Solomon SD, et al
    Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Circulation. 2018 Mar 11. pii: CIRCULATIONAHA.118.034222.
    PubMed     Text format     Abstract available


  8. VIJAYAKUMAR S, Vaduganathan M, Butler J
    Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.
    Circulation. 2018;137:1060-1073.
    PubMed     Text format     Abstract available


    January 2018
  9. IANIRO G, Cammarota G, Gasbarrini A
    Letter by Ianiro et al Regarding Article, "Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium".
    Circulation. 2018;137:213-214.
    PubMed     Text format    


  10. PLUTZKY J, Bakris G
    Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
    Circulation. 2018;137:130-133.
    PubMed     Text format    


    December 2017
  11. GIUGLIANO RP, Cannon CP, Blazing MA, Nicolau JC, et al
    Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT.
    Circulation. 2017 Dec 20. pii: CIRCULATIONAHA.117.030950.
    PubMed     Text format     Abstract available


    November 2017
  12. VERMA S, Mazer CD, Al-Omran M, Inzucchi SE, et al
    Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Circulation. 2017 Nov 13. pii: CIRCULATIONAHA.117.032031.
    PubMed     Text format     Abstract available


    October 2017
  13. LYTVYN Y, Bjornstad P, Udell JA, Lovshin JA, et al
    Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Circulation. 2017;136:1643-1658.
    PubMed     Text format     Abstract available


  14. YOUNG LH, Viscoli CM, Inzucchi SE, Kernan WN, et al
    Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1567-1568.
    PubMed     Text format    


  15. JIN-SHAN H, Xue-Bin L
    Letter by Jin-Shan and Xue-Bin Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1565-1566.
    PubMed     Text format    


  16. MUSSO G, Cassader M, Gambino R
    Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1563-1564.
    PubMed     Text format    


  17. WOLSK E, Claggett B, Diaz R, Dickstein K, et al
    Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
    Circulation. 2017;136:1560-1562.
    PubMed     Text format    


  18. PACKER M
    Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure.
    Circulation. 2017;136:1548-1559.
    PubMed     Text format     Abstract available


  19. BUTLER J, Anker SD
    The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Circulation. 2017;136:1459-1461.
    PubMed     Text format    


    September 2017
  20. WILSON PWF, Gagnon D
    Diabetes Mellitus and Control of Cardiovascular Disease Risk Factors: A Challenge to Improve Usual Care.
    Circulation. 2017;136:1204-1206.
    PubMed     Text format    


  21. STRIEPE K, Jumar A, Ott C, Karg MV, et al
    Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2017;136:1167-1169.
    PubMed     Text format    


  22. WANNER C, Lachin JM, Inzucchi SE, Fitchett D, et al
    Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease.
    Circulation. 2017 Sep 13. pii: CIRCULATIONAHA.117.028268.
    PubMed     Text format     Abstract available


  23. KAPPEL BA, Lehrke M, Schutt K, Artati A, et al
    Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Circulation. 2017;136:969-972.
    PubMed     Text format    


    August 2017
  24. SHAN K, Liu C, Liu BH, Chen X, et al
    Circular Non-Coding RNA HIPK3 Mediates Retinal Vascular Dysfunction in Diabetes Mellitus.
    Circulation. 2017 Aug 31. pii: CIRCULATIONAHA.117.029004.
    PubMed     Text format     Abstract available


  25. NAUCK MA, Meier JJ, Cavender MA, Abd El Aziz M, et al
    Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Circulation. 2017;136:849-870.
    PubMed     Text format     Abstract available


  26. SARDELLA G, Mancone M, Stio RE, Cavallo E, et al
    Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus.
    Circulation. 2017;136:602-604.
    PubMed     Text format    


  27. LAU DH, Nattel S, Kalman JM, Sanders P, et al
    Modifiable Risk Factors and Atrial Fibrillation.
    Circulation. 2017;136:583-596.
    PubMed     Text format     Abstract available


    June 2017
  28. HU L, Chang L, Zhang Y, Zhai L, et al
    Platelets Express Activated P2Y12 Receptor in Patients with Diabetes.
    Circulation. 2017 Jun 21. pii: CIRCULATIONAHA.116.026995.
    PubMed     Text format     Abstract available


  29. PAGIDIPATI NJ, Navar AM, Pieper KS, Green JB, et al
    Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial.
    Circulation. 2017 Jun 16. pii: CIRCULATIONAHA.117.027252.
    PubMed     Text format     Abstract available


    May 2017
  30. KOSIBOROD M, Cavender MA, Fu AZ, Wilding JP, et al
    Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study.
    Circulation. 2017 May 18. pii: CIRCULATIONAHA.117.029190.
    PubMed     Text format     Abstract available


  31. DALE C, Fatemifar G, Palmer T, White J, et al
    Causal Associations of Adiposity and Body Fat Distribution with Coronary Heart Disease, Stroke Subtypes and Type 2 Diabetes: A Mendelian Randomization Analysis.
    Circulation. 2017 May 12. pii: CIRCULATIONAHA.116.026560.
    PubMed     Text format     Abstract available


  32. GOLDBERG RB, Aroda VR, Bluemke DA, Barrett-Connor E, et al
    Effect of Long-term Metformin and Lifestyle in the Diabetes Prevention Program and its Outcome Study on Coronary Artery Calcium.
    Circulation. 2017 May 5. pii: CIRCULATIONAHA.116.025483.
    PubMed     Text format     Abstract available


  33. SAITO Y, Ogawa H, Morimoto T
    Response by Saito et al to Letter Regarding Article, "Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial".
    Circulation. 2017;135:e1010-e1011.
    PubMed     Text format    


  34. AHMED SB, Metcalfe A, Nerenberg K
    Letter by Ahmed et al Regarding Article, "Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial".
    Circulation. 2017;135:e1008-e1009.
    PubMed     Text format    


  35. VAN DE WERF F
    Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy?
    Circulation. 2017;135:1675-1676.
    PubMed     Text format    


    April 2017
  36. RAWSHANI A, Rawshani A, Franzen S, Eliasson B, et al
    Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus.
    Circulation. 2017;135:1522-1531.
    PubMed     Text format     Abstract available


  37. SORENSEN BM, Houben AJ, Martens RJ, Stehouwer CD, et al
    Response by Sorensen et al to Letters Regarding Article, "Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study".
    Circulation. 2017;135:e862-e863.
    PubMed     Text format    


  38. BRZEZINSKI RY, Berliner S, Shenhar-Tsarfaty S
    Letter by Brzezinski et al Regarding Article, "Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study".
    Circulation. 2017;135:e860-e861.
    PubMed     Text format    


  39. TSUDA K
    Letter by Tsuda Regarding Article, "Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study".
    Circulation. 2017;135:e858-e859.
    PubMed     Text format    


    February 2017
  40. YOUNG LH, Viscoli CM, Curtis JP, Inzucchi SE, et al
    Cardiac Outcomes After Ischemic Stroke or TIA: Effects of Pioglitazone in Patients with Insulin Resistance Without Diabetes.
    Circulation. 2017 Feb 28. pii: CIRCULATIONAHA.116.024863.
    PubMed     Text format     Abstract available


  41. CAVENDER MA, White WB, Jarolim P, Bakris GL, et al
    Serial Measurement of High Sensitivity Troponin I and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus in the EXAMINE Trial.
    Circulation. 2017 Feb 28. pii: CIRCULATIONAHA.116.024632.
    PubMed     Text format     Abstract available


  42. BELALCAZAR LM, Ballantyne CM
    Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials.
    Circulation. 2017;135:720-723.
    PubMed     Text format    


    January 2017
  43. MAKAM AN, Nguyen OK
    An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment.
    Circulation. 2017;135:180-195.
    PubMed     Text format     Abstract available


  44. LINDMAN BR
    The Diabetic HFpEF Phenotype: Is it Real and is it Worth Targeting Therapeutically?
    Circulation. 2017 Jan 4. pii: CIRCULATIONAHA.116.025957.
    PubMed     Text format     Abstract available


  45. KRISTENSEN SL, Mogensen UM, Jhund PS, Petrie MC, et al
    Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients with Heart Failure and Preserved Ejection Fraction. A Report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Tria
    Circulation. 2017 Jan 4. pii: CIRCULATIONAHA.116.024593.
    PubMed     Text format     Abstract available


    November 2016
  46. SAITO Y, Okada S, Ogawa H, Soejima H, et al
    Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes: 10-year Follow-up of a Randomized Controlled Trial.
    Circulation. 2016 Nov 15. pii: CIRCULATIONAHA.116.025760.
    PubMed     Text format     Abstract available


  47. WANG Q, Liu Y, Fu Q, Xu B, et al
    Inhibiting Insulin-Mediated beta2AR Activation Prevents Diabetes-Associated Cardiac Dysfunction.
    Circulation. 2016 Nov 4. pii: CIRCULATIONAHA.116.022281.
    PubMed     Text format     Abstract available


    October 2016
  48. BOZKURT B, Aguilar D, Deswal A, Dunbar SB, et al
    Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2016 Oct 31. pii: CIR.0000000000000450.
    PubMed     Text format    


  49. ALSHEHRY ZH, Mundra PA, Barlow CK, Mellett NA, et al
    Plasma Lipidomic Profiles Improve Upon Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes.
    Circulation. 2016 Oct 18. pii: CIRCULATIONAHA.116.023233.
    PubMed     Text format     Abstract available


  50. CAPODANNO D, Angiolillo DJ
    Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus.
    Circulation. 2016 Oct 11. pii: CIRCULATIONAHA.116.023164.
    PubMed     Text format     Abstract available


    September 2016
  51. SORENSEN BM, Houben AJ, Berendschot TT, Schouten JS, et al
    Prediabetes and Type 2 Diabetes are Associated with Generalized Microvascular Dysfunction: The Maastricht Study.
    Circulation. 2016 Sep 27. pii: CIRCULATIONAHA.116.023446.
    PubMed     Text format     Abstract available


  52. CHENG Z, Garikipati V, Nickoloff E, Wang C, et al
    Restoration of Hydrogen Sulfide Production in Diabetic Mice Improves Reparative Function of Bone Marrow Cells.
    Circulation. 2016 Sep 22. pii: CIRCULATIONAHA.116.022967.
    PubMed     Text format     Abstract available


  53. MANGIACAPRA F, Panaioli E, Colaiori I, Ricottini E, et al
    Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients)
    Circulation. 2016;134:835-7.
    PubMed     Text format    


  54. STOREY RF, Parker WA
    Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus.
    Circulation. 2016;134:793-6.
    PubMed     Text format    


    August 2016
  55. FRANCHI F, Rollini F, Aggarwal N, Hu J, et al
    A Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
    Circulation. 2016 Aug 24. pii: CIRCULATIONAHA.116.023402.
    PubMed     Text format     Abstract available


    July 2016
  56. HEERSPINK HJ, Perkins BA, Fitchett DH, Husain M, et al
    Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes: Cardiovascular and Kidney Effects, Potential Mechanisms and Clinical Applications.
    Circulation. 2016 Jul 28. pii: CIRCULATIONAHA.116.021887.
    PubMed     Text format     Abstract available


  57. YOON CH, Choi YE, Cha YR, Koh SJ, et al
    Diabetes-Induced Jagged 1 Overexpression in Endothelial Cells Causes Retinal Capillary Regression in a Murine Model of Diabetes Mellitus: Insights into Diabetic Retinopathy.
    Circulation. 2016 Jul 12. pii: CIRCULATIONAHA.116.014411.
    PubMed     Text format     Abstract available


  58. KAUL S
    Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?
    Circulation. 2016;134:94-6.
    PubMed     Text format    


    June 2016
  59. LOW WANG CC, Hess CN, Hiatt WR, Goldfine AB, et al
    Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.
    Circulation. 2016;133:2459-502.
    PubMed     Text format     Abstract available


    May 2016
  60. CORREA A
    Pre-gestational Diabetes and Congenital Heart Defects.
    Circulation. 2016 May 10. pii: CIRCULATIONAHA.116.022960.
    PubMed     Text format     Abstract available


  61. OYEN N, Diaz LJ, Leirgul E, Boyd HA, et al
    Pre-Pregnancy Diabetes and Offspring Risk of Congenital Heart Disease: A Nation-Wide Cohort Study.
    Circulation. 2016 May 10. pii: CIRCULATIONAHA.115.017465.
    PubMed     Text format     Abstract available


    April 2016
  62. QAMAR A, Bhatt DL
    Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease.
    Circulation. 2016;133:1512-5.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: